Trial Profile
Randomised, Double-blind, Phase II Trial of Adjuvant Durvalumab or Placebo for Completely Resected Esophageal Squamous Cell Carcinoma Previously Treated With Neoadjuvant Concurrent Chemoradiotherapy .
Status:
Not stated
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary)
- Indications Oesophageal cancer
- Focus Therapeutic Use
- 05 Dec 2019 Planned End Date changed from 1 Apr 2020 to 1 Dec 2021.
- 05 Dec 2019 Planned primary completion date changed from 1 Nov 2019 to 1 Jun 2021.
- 30 Aug 2018 Status changed from recruiting to active, no longer recruiting.